NASDAQ:RDUSRadius Health Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Radius Health Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.64 +0.03 (+0.24 %) (As of 08/11/2020 12:16 PM ET) Add Compare Share Today's Range$12.33Now: $12.64▼$12.9750-Day Range$11.62MA: $13.30▼$14.3852-Week Range$10.32Now: $12.64▼$29.97Volume9,226 shsAverage Volume779,690 shsMarket Capitalization$586.37 millionP/E RatioN/ADividend YieldN/ABeta1.12 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.1 Analyst's Opinion Consensus RatingRadius Health has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.38, Radius Health has a potential upside of 77.4% from its current price of $12.61.Amount of Analyst CoverageRadius Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesRadius Health has received 502 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRadius Health has received 400 “underperform” votes. (Add your “underperform” vote.)Community SentimentRadius Health has received 55.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote “Outperform” if you believe RDUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRadius Health does not currently pay a dividend.Dividend GrowthRadius Health does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Radius Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $330,250.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.92% of the stock of Radius Health is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Radius Health are expected to grow in the coming year, from ($2.66) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Radius Health is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Radius Health is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDUS Previous Symbol CUSIPN/A CIK1428522 Webwww.radiuspharm.com Phone617-551-4000Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio2.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$173.32 million Price / Sales3.38 Cash FlowN/A Price / Cash FlowN/A Book Value($0.92) per share Price / Book-13.74Profitability EPS (Most Recent Fiscal Year)($2.89) Net Income$-132,990,000.00 Net Margins-66.82% Return on EquityN/A Return on Assets-57.31%Miscellaneous Employees398 Outstanding Shares46,390,000Market Cap$586.37 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $12.64 +0.03 (+0.24 %) (As of 08/11/2020 12:16 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RDUS News and Ratings via Email Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter. Radius Health (NASDAQ:RDUS) Frequently Asked Questions How has Radius Health's stock been impacted by COVID-19 (Coronavirus)? Radius Health's stock was trading at $16.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS stock has decreased by 21.3% and is now trading at $12.64. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Radius Health? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Radius Health. When is Radius Health's next earnings date? Radius Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Radius Health. How were Radius Health's earnings last quarter? Radius Health Inc (NASDAQ:RDUS) posted its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.95) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.82) by $0.13. View Radius Health's earnings history. What price target have analysts set for RDUS? 8 equities research analysts have issued twelve-month price targets for Radius Health's stock. Their forecasts range from $14.00 to $28.00. On average, they anticipate Radius Health's stock price to reach $22.38 in the next year. This suggests a possible upside of 77.0% from the stock's current price. View analysts' price targets for Radius Health. Has Radius Health been receiving favorable news coverage? News headlines about RDUS stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Radius Health earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Radius Health. Who are some of Radius Health's key competitors? Some companies that are related to Radius Health include Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), I-Mab (IMAB), Seres Therapeutics (MCRB), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL) and Revance Therapeutics (RVNC). View all competitors. What other stocks do shareholders of Radius Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), EXACT Sciences (EXAS), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX). Who are Radius Health's key executives? Radius Health's management team includes the following people: Mr. Jesper Høiland, Pres, CEO & Director (Age 59)Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)Mr. Brian Nicholas Harvey, Advisor (Age 58)Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board What is Radius Health's stock symbol? Radius Health trades on the NASDAQ under the ticker symbol "RDUS." Who are Radius Health's major shareholders? Radius Health's stock is owned by many different retail and institutional investors. Top institutional investors include Emerald Advisers LLC (1.93%), Rhenman & Partners Asset Management AB (0.72%), Russell Investments Group Ltd. (0.30%), MERIAN GLOBAL INVESTORS UK Ltd (0.28%), Swiss National Bank (0.22%) and Mackay Shields LLC (0.16%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere. View institutional ownership trends for Radius Health. Which major investors are selling Radius Health stock? RDUS stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC. View insider buying and selling activity for Radius Health. Which major investors are buying Radius Health stock? RDUS stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Rhenman & Partners Asset Management AB, Rafferty Asset Management LLC, Swiss National Bank, Russell Investments Group Ltd., Virtus ETF Advisers LLC, Mackay Shields LLC, and ProShare Advisors LLC. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech. View insider buying and selling activity for Radius Health. How do I buy shares of Radius Health? Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Radius Health's stock price today? One share of RDUS stock can currently be purchased for approximately $12.64. How big of a company is Radius Health? Radius Health has a market capitalization of $586.37 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe. What is Radius Health's official website? The official website for Radius Health is www.radiuspharm.com. How can I contact Radius Health? Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
